Eyeing food allergy opportunity, GSK buys Rapt for $2.2B and its China asset

Rapt’s late 2024 deal to in-license most global rights to an immunology program sourced from China positioned the California biotech for a $2.2 billion takeout by GSK just 13 months later.

GSK plc (LSE:GSK; NYSE:GSK) believes ozureprubart from Rapt Therapeutics Inc. (NASDAQ:RAPT), now in a Phase IIb trial as a prophylaxis against food allergy, can become a best-in-class therapy with a dosing advantage over approved drug Xolair omalizumab. Results from the study, prestIgE, are due in 2027...